Restenosis treatments using nanoparticle-based drug delivery systems

Current Pharmaceutical Design

Volumn 19, Issue 35, 2013, Pages 6330-6339

  Gu, Zi ^a   Rolfe, Barbara E ^a   Thomas, Anita C ^b   Xu, Zhi Ping ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Drug delivery; Layered double hydroxide; Nanoparticle; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ALENDRONIC ACID; CARBOPOL 940; DIPYRIDAMOLE; DOXORUBICIN; FERRIC OXIDE; HEPARIN; HYDROXIDE; KN 911; LIPOSOME; LOW MOLECULAR WEIGHT HEPARIN; MACROGOL; MAGNETIC NANOPARTICLE; MAGNOLOL; NANOMATERIAL; NANOPARTICLE; NANOTUBE; NK 911; PACLITAXEL; PHTHALOCYANINE ZINC; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; POLYVINYL ALCOHOL; PROTEIN DERIVATIVE; RAPAMYCIN; TITANIUM NITRIDE OXIDE; TITANIUM OXIDE NANOTUBE; U 86983; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROTIC PLAQUE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; FEASIBILITY STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERCALATION COMPLEX; LIPOSOMAL DELIVERY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RESTENOSIS; REVIEW;

ANIMALS; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIPOSOMES; NANOPARTICLES; NANOTUBES; POLYMERS; PROTEINS; TITANIUM;

EID: 84887927940     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319350009     Document Type: Review

References (110)

1. Ross R, Glomset JA. Atherosclerosis and arterial smooth muscle cell. Science 1973; 180: 1332-9.
2. Ferns GAA, Avades TY. The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol 2000; 81: 63-88.
3. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57: 791-804.
4. Schwartz SM, Deblois D, Obrien ERM. The intima: soil for atherosclerosis and restenosis Circ Res 1995; 77: 445-65.
5. Schiele TM, Krotz F, Klauss V. Vascular restenosis-striving for therapy. Expert Opin Pharmacother 2004; 5: 2221-32.
6. Newby AC. An overview of the vascular response to injury: a tribute to the late Ross. Toxicol Lett 2000; 112: 519-29.
7. Campbell GR, Chamleycampbell JH. Smooth muscle phenotypic modulation: role in atherogenesis. Med Hypotheses 1981; 7: 729-35.
8. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
9. Campbell GR, Chamley-Campbell JH, Burnstock G. Differentiation and phenotypic modulation of arterial smooth muscle. In: Schwartz CJ, Werthessen NT, Wolf S, editors. Structure and function of the circulation. Orlando: Plenum Press; 1981. p. 357-99.
10. Campbell GR, Campbell JH, Manderson JA, Horrigan S, Rennick RE. Arterial smooth muscle-a multifunctional mesenchymal cell. Arch Pathol Lab Med 1988; 112: 977-86.
11. Campbell GR, Campbell JH, Manderson JA, Horrigan S, Rennick RE. Arterial smooth muscle: a multifunctional mesenchymal cell. Arch Pathol Lab Med 1988; 112: 977-86.
12. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
13. Rensing BJ, Hermans WR, Strauss BH, Serruys PW. Regional differences in elastic recoil after percutaneous transluminal coronary angioplasty: a quantitative angiographic study. J Am Coll Cardiol 1991; 17: B34-B8.
14. Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 1987; 60: B20-B8.
15. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992; 20: 1284-93.
16. Van Belle E, Susen S, Jude B, Bertrand ME. Drug-eluting stents: trading restenosis for thrombosis? J Thromb Haemost 2007; 5: 238-45.
17. Van Belle E, Bauters C, Asahara T, Isner JM. Endothelial regrowth after arterial injury: from vascular repair to therapeutics. Cardiovascular Research 1998; 38: 54-68.
18. Schwartz SM, Campbell GR, Campbell JH. Replication of smooth muscle cells in vascular disease Circ Res 1986; 58: 427-44.
19. Curcio A, Torella D, Indolfi C. Mechanisms of Smooth Muscle Cell Proliferation and Endothelial Regeneration After Vascular Injury and Stenting-Approach to Therapy. Circ J 2011; 75: 1287-96.
20. Zargham R. Preventing restenosis after angioplasty: a multistage approach. Clin Sci 2008; 114: 257-64.
21. Cipollone F, Marini M, Fazia M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 2001; 21: 327-34.
22. Landzberg BR, Frishman WH, Lerrick K. Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures. Prog Cardiovasc Dis 1997; 39: 361-98.
23. Rodriguez AE. Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era. Expert Opin Emerg Drugs 2009; 14: 561-76.
24. Lefkovits J, Topol EJ. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Prog Cardiovasc Dis 1997; 40: 141-58.
25. Tiroch KA, Byrne RA, Kastrati A. Pharmacological prevention and management of restenosis. Expert Opin Pharmacother 2010; 11: 1855-72.
26. Wilensky RL, Tanguay JF, Ito S, et al. Heparin infusion prior to stenting (HIPS) trial: Final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia. Am Heart J 2000; 139: 1061-70.
27. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-9.
28. Ellis SG, Roubin GS, Wilentz J, Lin S, Douglas JS, King SB. Results of a randomized trial of heparin and aspirin vs aspirin alone for prevention of acute closure (AC) and restenosis (R) after angioplasty (PTCA). Circulation 1987; 76: 213-.
29. Labhasetwar V, Song CX, Levy RJ. Nanoparticle drug delivery system for restenosis. Adv Drug Deliv Rev 1997; 24: 63-85.
30. Edelman ER, Karnovsky MJ. Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation 1994; 89: 770-6.
31. Maluenda G, Lemesle G, Waksman R. A Critical Appraisal of the Safety and Efficacy Drug-Eluting Stents. Clin Pharmacol Ther 2009; 85: 474-80.
32. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol 2010; 56: S1-S42.
33. De M, Ghosh PS, Rotello VM. Applications of nanoparticles in biology. Adv Mater 2008; 20: 4225-41.
34. Brito L, Amiji M. Nanoparticulate carriers for the treatment of coronary restenosis. Int J Nanomedicine 2007; 2: 143-61.
35. Kavanagh CA, Rochev YA, Gallagher WA, Dawson KA, Keenan AK. Local drug delivery in restenosis injury: thermoresponsive copolymers as potential drug delivery systems. Pharmacol Ther 2004; 102: 1-15.
36. Luderer F, Sternberg K, Rohm HW, et al. Biodegradable Sirolimus-loaded Poly(lactide) Nanoparticles as Delivery Systems for the Prevention of Restenosis in Coronary Stent Application. In: Dossel O, Schlegel WC, editors. World Congress on Medical Physics and Biomedical Engineering, Vol 25, Pt 10-Biomaterials, Cellular and Tissue Engineering, Artificial Organs. New York: Springer; 2009. p. 193-6.
37. Fishbein I, Chorny M, Banai S, et al. Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler Thromb Vasc Biol 2001; 21: 1434-9.
38. Banai S, Chorny M, Gertz SD, et al. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials 2005; 26: 451-61.
39. Guzman LA, Labhasetwar V, Song CX, et al. Local intraluminal infusion of biodegradable polymeric nanoparticles-A novel approach for prolonged drug delivery after balloon angioplasty. Circulation 1996; 94: 1441-8.
40. Cohen-Sela E, Rosenzweig O, Gao JC, et al. Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J Control Release 2006; 113: 23-30.
41. Humphrey WR, Erickson LA, Simmons CA, et al. The effect of intramural delivery of polymeric nanoparticles loaded with the antiproliferative 2-aminochromone U-86983 on neointimal hyperplasia development in balloon-injured porcine coronary arteries. Adv Drug Deliv Rev 1997; 24: 87-108.
42. Song CX, Labhasetwar V, Murphy H, et al. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Control Release 1997; 43: 197-212.
43. Xu XH, Lu P, Guo MQ, Fang MZ. Cross-linked gelatin/nanoparticles composite coating on micro-arc oxidation film for corrosion and drug release. Appl Surf Sci 2010; 256: 2367-71.
44. Chen MC, Tsai HW, Liu CT, et al. A nanoscale drug-entrapment strategy for hydrogel-based systems for the delivery of poorly soluble drugs. Biomaterials 2009; 30: 2102-11.
45. Jo YS, van der Vlies AJ, Gantz J, et al. Micelles for Delivery of Nitric Oxide. J Am Chem Soc 2009; 131: 14413-8.
46. Uwatoku T, Shimokawa H, Abe K, et al. Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats. Circ Res 2003; 92: E62-E9.
47. Nakanishi T, Fukushima S, Okamoto K, et al. Development of the polymer micelle carrier system for doxorubicin. J Control Release 2001; 74: 295-302.
48. Deshpande D, Devalapally H, Amiji M. Enhancement in antiproliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles. Pharm Res 2008; 25: 1936-47.
49. Feng SS, Zeng WT, Lim YT, et al. Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment. Nanomedicine 2007; 2: 333-44.
50. Zou WW, Cao GQ, Xi YW, Zhang N. New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles. Drug Deliv 2009; 16: 15-23.
51. Labhasetwar V, Song CX, Humphrey W, Shebuski R, Levy RJ. Arterial uptake of biodegradable nanoparticles: Effect of surface modifications. J Pharm Sci 1998; 87: 1229-34.
52. Song CX, Labhasetwar V, Cui XM, Underwood T, Levy RJ. Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: Results with an acute dog model. J Control Release 1998; 54: 201-11.
53. Mei L, Sun HF, Jin X, et al. Modified paclitaxel-loaded nanoparticles for inhibition of hyperplasia in a rabbit arterial balloon injury model. Pharm Res 2007; 24: 955-62.
54. Bangham AD, Haydon DA. Ultrastructure of membranes: bimolecular organization. Br Med Bull 1968; 24: 124-6.
55. Bowey K, Tanguay JF, Tabrizian M. Liposome technology for cardiovascular disease treatment and diagnosis. Expert Opin Drug Deliv 2012; 9: 249-65.
56. Labhasetwar V, Chen BR, Muller DWM, et al. Gene-based therapies for restenosis. Adv Drug Deliv Rev 1997; 24: 109-20.
57. Chen CYC, Wu CH. Magnolol encapsulated by liposome in inhibiting smooth muscle cell proliferation. J Chin Chem Soc 2008; 55: 517-21.
58. Chen CYC. Magnolol encapsulated by different acyl chain length of liposomes on inhibiting proliferation of smooth muscle cells. J Taiwan Inst Chem Eng 2009; 40: 380-6.
59. Magaraggia M, Visona A, Furlan A, et al. Inactivation of vascular smooth muscle cells photosensitised by liposome-delivered Zn(II)-phthalocyanine. J Photochem Photobiol B-Biol 2006; 82: 53-8.
60. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998; 38: 375-88.
61. Danenberg HD, Golomb G, Groothuis A, et al. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation 2003; 108: 2798-804.
62. Danenberg HD, Fishbein I, Gao JC, et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002; 106: 599-605.
63. Antimisiaris SG, Koromila G, Michanetzis G, Missirlis YF. Liposome coated stents: A method to deliver drugs to the site of action and improve stent blood-compatibility. J Liposome Res 2006; 16: 303-9.
64. Markovsky E, Koroukhov N, Golomb G. Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. Nanomedicine 2007; 2: 545-53.
65. Kolodgie FD, John M, Khurana C, et al. Sustained reduction of instent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 2002; 106: 1195-8.
66. Margolis J, McDonald J, Heuser R, et al. Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent Restenosis I (SNAPIST-1): A first-in-human safety and dose-finding study. Clinical Cardiology 2007; 30: 165-70.
67. Ferruccio Trifiro AV. Hydrotalcite-like anionic clays. In: Jerry L. Atwood JEDD, David D. Macnicol, Fritz Vogtle, editor. Comprehensive supramolecular chemistry New York: Pergamon Press; 1996. p. 251-91.
68. Braterman PS, Xu ZP, Yarberry F. Layered Double Hydroxides (LDHs). In: Auerbach SM, Carrado KA, Dutta PK, editors. Handbook of Layered Materials. New York: Marcel Dekker; 2004. p. 373-474.
69. Cavani F, Trifirò F, Vaccari A. Hydrotalcite-type anionic clays: Preparation, properties and applications. Catal Today 1991; 11: 173-301.
70. Lin MS, Sun P, Yu HY. Evaluation of buffering capacity and acid neutralizing-pH time profile of antacids. J Formos Med Assoc 1998; 97: 704-10.
71. Choy JH, Kwak SY, Jeong YJ, Park JS. Inorganic layered double hydroxides as nonviral vectors. Angew Chem-Int Edit 2000; 39: 4042-5.
72. Xu ZP, Lu GQ. Layered double hydroxide nanomaterials as potential cellular drug delivery agents. Pure Appl Chem 2006; 78: 1771-9.
73. Xu ZP, Zeng QH, Lu GQ, Yu AB. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci 2006; 61: 1027-40.
74. Oh JM, Choi SJ, Kim ST, Choy JH. Cellular uptake mechanism of an inorganic nanovehicle and its drug conjugates: Enhanced efficacy due to clathrin-mediated endocytosis. Bioconjug Chem 2006; 17: 1411-7.
75. Musumeci AW, Schiller TL, Xu ZP, Minchin RF, Martin DJ, Smith SV. Synthesis and characterization of dual radiolabeled layered double hydroxide nanoparticles for use in in vitro and in vivo nanotoxicology studies. J Phys Chem C 2010; 114: 734-40.
76. Xu ZP, Niebert M, Porazik K, et al. Subcellular compartment targeting of layered double hydroxide nanoparticles. J Control Release 2008; 130: 86-94.
77. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977; 265: 625-6.
78. Gu Z, Thomas AC, Xu ZP, Campbell JH, Lu GQ. In vitro sustained release of LMWH from MgAl-layered double hydroxide nanohybrids. Chem Mat 2008; 20: 3715-22.
79. Gu Z, Rolfe BE, Thomas AC, Campbell JH, Lu GQ, Xu ZP. Heparin-related nanomaterials. In: Piyathilake DE, Liang R, editors. Heparin, properties, uses and side effects: Nova Publisher; 2012. p. 159-78.
80. Gu Z, Rolfe BE, Xu ZP, Thomas AC, Campbell JH, Lu GQM. Enhanced effects of low molecular weight heparin intercalated with layered double hydroxide nanoparticles on rat vascular smooth muscle cells. Biomaterials 2010; 31: 5455-62.
81. Gu Z, Rolfe BE, Thomas AC, Campbell JH, Lu GQ, Xu ZP. Cellular trafficking of low molecular weight heparin incorporated in layered double hydroxide nanoparticles in rat vascular smooth muscle cells. Biomaterials 2011; 32: 7234-40.
82. Bass JD, Grosso D, Boissiere C, Belamie E, Coradin T, Sanchez C. Stability of mesoporous oxide and mixed metal oxide materials under biologically relevant conditions. Chem Mater 2007; 19: 4349-56.
83. Peng L, Eltgroth ML, LaTempa TJ, Grimes CA, Desai TA. The effect of TiO2 nanotubes on endothelial function and smooth muscle proliferation. Biomaterials 2009; 30: 1268-72.
84. Peng LL, Mendelsohn AD, LaTempa TJ, Yoriya S, Grimes CA, Desai TA. Long-Term Small Molecule and Protein Elution from TiO2 Nanotubes. Nano Letters 2009; 9: 1932-6.
85. Dittmar K, de Labrouhe AT, Piveteau LD, Hofmann H. Nanostructured Ceramic Coatings for Drug Delivery. In: Shastri VP, Lendlein A, Liu L, Mikos A, Mitragotri S, editors. Advances in Material Design for Regenerative Medicine, Drug Delivery and Targeting/Imaging. Warrendale: Materials Research Society; 2009. p. 51-7.
86. Windecker S, Mayer I, De Pasquale G, et al. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation 2001; 104: 928-33.
87. Erhlich P. Collected studies on immunity. New York: John Wiley; 1906. p. 442-7.
88. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364: 583-91.
89. Douglas JS. Pharmacologic approaches to restenosis prevention. Am J Cardiol 2007; 100: 10K-6K.
90. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans-Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
91. Slottow TLP, Waksman R. Overview of the 2006 Food and Drug Administration circulatory system devices panel meeting on drug eluting stent thrombosis. Catheter Cardiovasc Interv 2007; 69: 1064-74.
92. Casi G, Neri D. Antibody-drug conjugates: Basic concepts, examples and future perspectives. J Control Release 2012; 161: 422-8.
93. Thomas AC. Targeted delivery of anti-restenotic agents: The University of Queensland; 2003.
94. Thomas AC, Campbell JH. Conjugation of an antibody to crosslinked fibrin for targeted delivery of anti-restenotic drugs. Journal of Controlled Release 2004; 100: 357-77.
95. Thomas AC, Campbell JH. Timecourse of fibrin deposition and removal after arterial injury. Thromb Res 2003; 109: 65-9.
96. Thomas AC, Campbell JH. Targeted delivery of heparin and LMWH using a fibrin antibody prevents restenosis. Atherosclerosis 2004; 176: 73-81.
97. Gu Z, Rolfe BE, Xu ZP, Campbell JH, Lu GQ, Thomas AC. Antibody-targeted drug delivery to injured arteries using layered double hydroxide nanoparticles. Adv Healthc Mater 2012; 1: 669-73.
98. Lestini BJ, Sagnella SM, Xu Z, et al. Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J Control Release 2002; 78: 235-47.
99. Huang GF, Zhou ZM, Srinivasan R, et al. Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. Biomaterials 2008; 29: 1676-85.
100. Srinivasan R, Marchant RE, Sen Gupta A. In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes. J Biomed Mater Res Part A 2010; 93A: 1004-15.
101. Tsuruta W, Tsurushima H, Yamamoto T, Suzuki K, Yamazaki N, Matsumura A. Application of liposomes incorporating doxorubicin with sialyl Lewis X to prevent stenosis after rat carotid artery injury. Biomaterials 2009; 30: 118-25.
102. Chorny M, Fishbein I, Yellen BB, et al. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 8346-51.
103. Polyak B, Fishbein I, Chorny M, et al. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steed stents. Proc Natl Acad Sci USA 2008; 105: 698-703.
104. Chorny M, Hood E, Levy RJ, Muzykantov VR. Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. J Control Release 2010; 146: 144-51.
105. Chanan-Khan A, Szebeni J, Savay S, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003; 14: 1430-7.
106. Sabnis A, Rahimi M, Chapman C, Nguyen KT. Cytocompatibility studies of an in situ photopolymerized thermoresponsive hydrogel nanoparticle system using human aortic smooth muscle cells. J Biomed Mater Res Part A 2009; 91A: 52-9.
107. Haycox CL, Ratner BD. In vitro platelet interactions in whole human blood exposed to biomaterial surfaces: insights on blood compatibility. J Biomed Mater Res 1993; 27: 1181-93.
108. GuyCaffey JK, Bodepudi V, Bishop JS, Jayaraman K, Chaudhary N. Novel polyaminolipids enhance the cellular uptake of oligonucleotides. J Biol Chem 1995; 270: 31391-6.
109. Ostomel TA, Shi Q, Stoimenov PK, Stucky GD. Metal oxide surface charge mediated Hemostasis. Langmuir 2007; 23: 11233-8.
110. Baker SE, Sawvel AM, Zheng N, Stucky GD. Controlling bioprocesses with inorganic surfaces: Layered clay hemostatic agents. Chem Mater 2007; 19: 4390-2.